Immunome Expands Team with Stock Options Amid Advancements in Cancer Therapy Development

Immunome Bolsters Workforce with Inducement Awards Amid Cancer Therapy Advancements

Immunome, Inc., a biotechnology firm based in Bothell, Washington, takes a significant step forward in its talent acquisition strategy by announcing the granting of inducement awards to 15 new employees. On December 2, 2024, the company issues non-statutory stock options for a total of 210,500 shares of common stock under its 2024 Inducement Plan. The options are priced at $14.08 per share, corresponding to the company’s closing sales price on the grant date. This strategic move aims to attract and retain skilled professionals as Immunome seeks to enhance its capabilities in developing cutting-edge cancer therapies.

The stock options are structured to vest over a four-year period, with 25% of the options becoming available on the one-year anniversary of the vesting commencement date. The remaining options will vest monthly over the following three years, contingent upon the employees' ongoing service. This vesting schedule not only incentivizes long-term commitment but also aligns the interests of the new hires with the overall goals of Immunome, which focuses on pioneering targeted therapies for cancer treatment. The company’s leadership, recognized for their expertise in the design and commercialization of advanced treatments such as antibody-drug conjugates (ADCs), plays a crucial role in guiding these new initiatives.

Immunome’s current pipeline highlights its commitment to innovation in the oncology space. Notably, the company is advancing AL102, a gamma secretase inhibitor currently in Phase 3 clinical trials for desmoid tumors. Additionally, two ADCs—IM-1021 and IM-3050—are on track for Investigational New Drug (IND) applications expected to be submitted by the first quarter of 2025. These developments underscore Immunome’s dedication to enhancing cancer patient outcomes through the introduction of first-in-class and best-in-class therapies. As the company expands its team and capabilities, it positions itself to make significant contributions to the field of oncology.

In addition to the employee inducement awards, Immunome issues a cautionary statement regarding forward-looking statements, acknowledging the inherent uncertainties in the biotechnology sector. The company recognizes that actual results may vary from projections, emphasizing the dynamic nature of drug development and clinical trials. For further information on Immunome’s initiatives and pipeline, interested parties can visit their official website at www.immunome.com.